Table 4.
Complications Data
| Author | Year | Patients | Drains | Complication Rate | Hematoma | Seroma | NAC Necrosis/Epidermolysis | Dehiscence/Infection | Revision Rate | Transient Hypoesthesia |
|---|---|---|---|---|---|---|---|---|---|---|
| Coskun et al17 | 2001 | 32 | N | 33% (8/32) | * | * | 1 | NR | NR | 1 (3%) |
| Wiesman et al18 | 2004 | 174 | NR | 28.7% (50/174) | * | * | 0 | 2 | NR | NR |
| Handschin et al19 | 2007 | 100 | Y | 25% (25/100) | 9 | 8 | 7 | 1 | 7 (7%) | 6 (6%) |
| Tashkandi et al20 | 2004 | 24 | Y | 0% (0/24) | 0 | 0 | 0 | 0 | 0 (0%) | NR |
| Fan et al21 | 2009 | 65 | Y | 4.6% (3/65) | 0 | 1 | 2 | 0 | NR | NR |
| Murali et al22 | 2011 | 20 | Y | 10% (2/20) | 1 | 1 | NR | NR | NR | NR |
| Li et al23 | 2012 | 41 | Y | 12.1% (5/41) | 4 | 1 | NR | NR | 2 (4.87%) | 4 (9.75%) |
| Kasielska and Antoszewski24 | 2013 | 113 | Y | 12.4% (14/113) | 8 | 4 | 1 | 1 | NR | 11 (9.7%) |
| Sarkar et al25 | 2014 | 12 | Y | 25% (3/12) | 1 | 2 | NR | NR | NR | NR |
| Shirol9 | 2016 | 20 | N | 5% (1/20) | 1 | NR | NR | NR | 1 (5%) | NR |
| Khalil et al26 | 2017 | 52 | N | 0% (0/52) | 0 | 0 | 0 | 0 | 1 (1.9%) | 10 (19.2%) |
| Thiénot et al27 | 2017 | 9 | Y | 22.2% (2/9) | 1 | 0 | 0 | 1 | NR | NR |
| Wyrick et al28 | 2018 | 52 | Y/N | 11.5% (6/52) | 2 | 4 | 0 | 0 | NR | NR |
| Akhtar et al29 | 2019 | 60 | N | 8.3% (5/60) | 5 | 0 | 0 | NR | 2 (3.3%) | NR |
| Varlet et al30 | 2019 | 12 | Y | 8.3% (1/12) | 0 | 1 | 0 | 0 | NR | NR |
| Yao et al8 | 2019 | 22 | Y | 4.5% (1/22) | 1 | 0 | 0 | 0 | 0 (0%) | 1 (4.5%) |
| Sim et al31 | 2020 | 304 | N | 6.6% (20/304) | 20 | 0 | NR | NR | 43 (14.1%) | NR |
| Total | 1112 | 13.1% (146/1112) | 5.8% (53/906) | 2.4% (22/906) |
*
As hematoma and seroma rates were reported together, these values did not contribute to the calculated overall seroma and hematoma complication rates.
NR, not recorded.